lopinavir (Kaletra) Report issue

Small molecule Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lopinavir (ABT-378) is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir, under the trade names Kaletra.   NCATS

Chemistry

  • SMILES: CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)COC3=C(C)C=CC=C3C)CC4=CC=CC=C4
  • InChIKey: KJHKTHWMRKYKJE-SUGCFTRWSA-N
  • Mol. Mass: 628.8008
  • ALogP: 4.33
  • ChEMBL Molecule:
    lopinavir  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( ritonavir (Norvir), lopinavir (Kaletra) - other names: lopinavir: ritonavir, lopinavir/ritonavir )

Alternative names

a-157378-0 | a-157378.0 | abt-378 | aluvia | aluviran | kaletra | koletra | lopimune | lopinavir | lopinavir mixture with ritonavir | lopinavir / ritonavir | lopinavir/ritonavir | lopinavir-ritonavir drug combination | lpv

Organizations (360)

Research & Development (351)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (60)

Approved Indications (1)


 

HIV Infections

Experimental Indications - Clinical Trial Phases 1-4 (60)


 

Acquired Immunodeficiency Syndrome (Phase 4)

AIDS-Related Opportunistic Infections (Phase 4)

Antiretroviral Therapy, Highly Active (Phase 4)

Astrocytoma (Phase 2)

Atrophy (Phase 4)

Brain Neoplasms (Phase 2)

Breast Feeding (Phase 3)

Cardiovascular Diseases (Phase 4)

Coronavirus (Phase 2)

Coronavirus Infections (Phase 4)

COVID-19 (Phase 4)

Drug Interactions (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Dyslipidemias (Phase 4)

Ependymoma (Phase 2)

Fenofibrate (Phase 1)

General Surgery (Phase 3)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Gliosarcoma (Phase 2)

Glucose Metabolism Disorders (Phase 4)

Glucuronosyltransferase (Phase 1)

Healthy Volunteers (Phase 4)

Hepatitis B (Phase 2)

Hepatitis C (Phase 3)

HIV (Phase 4)

HIV-1 (Phase 4)

HIV-Associated Lipodystrophy Syndrome (Phase 4)

HIV Infections ()

HIV Seropositivity (Phase 2)

Hypercholesterolemia (Phase 4)

Hypertriglyceridemia (Phase 1)

Insulin Resistance (Phase 1)

Lipodystrophy (Phase 4)

Lopinavir (Phase 4)

Lung Diseases (Phase 2/Phase 3)

Lymphoma (Phase 2)

Malaria (Phase 3)

Malnutrition (Phase 4)

Metabolic Diseases (Phase 4)

Neoplasms (Phase 2)

Oligodendroglioma (Phase 2)

Parasitic Diseases (Phase 1/Phase 2)

Pharmacokinetics (Phase 1)

Pneumonia (Phase 4)

Post-Exposure Prophylaxis (Phase 3)

Pregnancy (Phase 4)

Protease Inhibitors (Phase 1)

Proteinuria (Phase 4)

Respiratory Distress Syndrome (Phase 1/Phase 2)

Respiratory Tract Infections (Phase 3)

Sarcoma, Kaposi (Phase 4)

SARS-CoV-2 (Phase 4)

Severe Acute Respiratory Syndrome (Phase 3)

Therapeutic Equivalency (Phase 1)

Therapeutics (Phase 1)

Treatment Failure (Phase 4)

Tuberculosis (Phase 4)

Uterine Cervical Diseases (Phase 2)

Virus Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 318
  • # of Trial Organizations: 351

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue